Onsite
16 - 18 November 2024
The congress symposium is no longer available
European Society for Paediatric Endocrinology, 2024 (ESPE)
Presentation materials
Saturday, 16 November 2024
POSTER
Impact of Idiopathic Short Stature (ISS) on children’s well-being
Anders Juul1,2,3; Agnes Linglart4; Michael Højby Rasmussen5; Tina Lund Leunbach5; Alberto Pietropoli6; Mikkel H Pedersen7; Lasse de Fries Jensen5
MATERIALS AVAILABLE
POSTER
Somapacitan is effective and well tolerated in Chinese children with GHD: 52-week results from the randomized phase 3 REAL6 trial
Junfen Fu1; Xinran Cheng2; Michael Højby3; Chunxiu Gong4; Tina Lund Leunbach3; Yanhong Li5; Haiyan Wei6; Yu Zhu7; Yining Zhang8; Yan Zhong9 on behalf of the REAL6 study group
MATERIALS AVAILABLE
Sunday, 17 November 2024
POSTER
Health care provider perspectives on Mallya Connectivity Cap & App for long-acting growth hormone in Slovenia
Primož Kotnik1,2; Klemen Dovč1,2; Barbara Murn Berkopec2; Liam McMorrow3; Tadej Battelino1,2
MATERIALS AVAILABLE
Monday, 18 November 2024
ORAL PRESENTATION
Response to daily and weekly recombinant human growth hormone treatment in children born small for gestational age is predicted more accurately by pre-treatment blood transcriptome than clinical variables
Terence Garner1; Philip Murray1,2; Michael Højby3; Ryan Anthony Ard3; Peter Clayton1,2; Adam Stevens1
MATERIALS AVAILABLE
ORAL PRESENTATION
Pharmacodynamic endpoints after once-weekly Somapacitan in children with GHD: 3-year results from REAL4 phase 3 study
Bradley S. Miller1; Joanne C. Blair2; Michael Højby Rasmussen3; Aristides Maniatis4; Jun Mori5; Volker Böttcher6; Ho-Seong Kim7; Michel Polak8; and Reiko Horikawa9
MATERIALS AVAILABLE
Keywords